



Consensus Standards Approval Committee (CSAC) Measure Evaluation Recusals

The [NQF CDP Conflict of Interest Policy](#) requires that CSAC members identified as having a potential conflict of interest in relation to specific measures must recuse themselves from evaluation and voting on those measures when seated on the Committee.

In the review of disclosure of interests submitted by CSAC members, NQF is requiring the following recusals be made during the October 11, 2016 CSAC conference call.

CSAC Member Recusals for Measures Reviewed on the October 11, 2016 Conference Call

Measure Number	Measure Title	Measure Steward	NQF Project	CSAC Member Recusals
1857	HER2 negative or undocumented breast cancer patients spared treatment with HER2-targeted therapies	American Society of Clinical Oncology	Cancer Project 2015-2017	Shelley Fuld Nasso CEO, National Coalition for Cancer Survivorship
1878	HER2 testing for overexpression or gene amplification in patients with breast cancer	American Society of Clinical Oncology	Cancer Project 2015-2017	Shelley Fuld Nasso CEO, National Coalition for Cancer Survivorship